{
    "clinical_study": {
        "@rank": "131409", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "0.01 mg/kg CPG 7909 plus Herceptin\u00ae"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "0.04 mg/kg CPG 7909 plus Herceptin\u00ae"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "arm_group_type": "Experimental", 
                "description": "0.16 mg/kg CPG 7909 plus Herceptin\u00ae"
            }, 
            {
                "arm_group_label": "Cohort 4", 
                "arm_group_type": "Experimental", 
                "description": "0.32 mg/kg CPG 7909 plus Herceptin\u00ae"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if the combination of CPG 7909 and Herceptin is\n      safe and effective in the treatment of metastatic breast cancer.\n\n      RATIONALE: There is preclinical data that supports the hypothesis that CPG 7909 may\n      potentiate the action of Herceptin.  This Phase I/II study is designed to evaluate the\n      safety and efficacy of the combination treatment of CPG 7909 and Herceptin in patients with\n      metastatic breast cancer who have previously been treated with Herceptin and chemotherapy.\n\n      SCHEDULE: Patients will receive CPG 7909 weekly for up to six months."
        }, 
        "brief_title": "Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer", 
        "completion_date": {
            "#text": "June 2003", 
            "@type": "Actual"
        }, 
        "condition": "Carcinoma, Metastatic Breast", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Carcinoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "Phase II part of study not initiated because the development plan modified the route of\n      administration to subcutaneous injection."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "INCLUSION CRITERIA Inclusion Criteria\n\n          -  Histologically confirmed breast cancer with metastases.\n\n          -  Tumor that has overexpression of HER2 as documented by being either FISH-positive or\n             HER2/neu 3+ confirmed by immunohistochemistry.\n\n          -  Patients must be candidates for single agent Herceptin treatment according to the\n             Herceptin\u00ae label.\n\n        Exclusion Criteria\n\n          -  Any prior therapy with anthracycline + Herceptin\u00ae.\n\n          -  Significant cardiovascular disease (e.g., NYHA class 3 congestive heart failure,\n             myocardial infarction within the past 6 months, unstable angina; coronary angioplasty\n             within the past 6 months, uncontrolled atrial or ventricular cardiac arrhythmias) or\n             left ventricular ejection fraction < 50%."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 28, 2002", 
        "id_info": {
            "nct_id": "NCT00031278", 
            "org_study_id": "C005", 
            "secondary_id": [
                "C005", 
                "A8501020"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Cohort 1", 
                "description": "Each 0.01 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.", 
                "intervention_name": "CPG 7909", 
                "intervention_type": "Drug", 
                "other_name": "PF-3512676, ProMune"
            }, 
            {
                "arm_group_label": "Cohort 1", 
                "description": "Herceptin\u00ae will be administered at a dose of 2 mg/kg IV according to the Herceptin\u00ae package insert", 
                "intervention_name": "Herceptin\u00ae", 
                "intervention_type": "Drug", 
                "other_name": "trastuzumab"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "description": "Each 0.04 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.", 
                "intervention_name": "CPG 7909", 
                "intervention_type": "Drug", 
                "other_name": "PF-3512676, ProMune"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "description": "Herceptin\u00ae will be administered at a dose of 2 mg/kg IV according to the Herceptin\u00ae package insert", 
                "intervention_name": "Herceptin\u00ae", 
                "intervention_type": "Drug", 
                "other_name": "trastuzumab"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "description": "Each 0.16 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.", 
                "intervention_name": "CPG 7909", 
                "intervention_type": "Drug", 
                "other_name": "PF-3512676, ProMune"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "description": "Herceptin\u00ae will be administered at a dose of 2 mg/kg IV according to the Herceptin\u00ae package insert", 
                "intervention_name": "Herceptin\u00ae", 
                "intervention_type": "Drug", 
                "other_name": "trastuzumab"
            }, 
            {
                "arm_group_label": "Cohort 4", 
                "description": "Each 0.32 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.", 
                "intervention_name": "CPG 7909", 
                "intervention_type": "Drug", 
                "other_name": "PF-3512676, ProMune"
            }, 
            {
                "arm_group_label": "Cohort 4", 
                "description": "Herceptin\u00ae will be administered at a dose of 2 mg/kg IV according to the Herceptin\u00ae package insert", 
                "intervention_name": "Herceptin\u00ae", 
                "intervention_type": "Drug", 
                "other_name": "trastuzumab"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Trastuzumab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Metastatic", 
            "Breast", 
            "Cancer", 
            "immunotherapy", 
            "CPG 7909"
        ], 
        "lastchanged_date": "May 26, 2011", 
        "link": {
            "description": "Click here for more information on the study sponsor", 
            "url": "http://www.coleypharma.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Farmington", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06030"
                    }, 
                    "name": "Univ. of Connecticut Health Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Plantation", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33324"
                    }, 
                    "name": "Cancer Research Network, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21201"
                    }, 
                    "name": "Greenebaum Cancer Center at Univ. of Maryland"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Dana-Farber Cancer Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109"
                    }, 
                    "name": "Comprehensive Cancer Center, University of Michigan"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Livingston", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07039"
                    }, 
                    "name": "Cancer Center at Saint Barnabas Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15213"
                    }, 
                    "name": "Univ. of Pittsburgh Cancer Institute, Magee Women's Hosp."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Burlington", 
                        "country": "United States", 
                        "state": "Vermont", 
                        "zip": "05401"
                    }, 
                    "name": "Fletcher Allen Health Care"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase I/II Open Label, Multi-Center Study For The Evaluation Of The Combination Of CpG 7909 And Herceptin\u00ae In Patients With Metastatic Breast Cancer", 
        "overall_official": {
            "affiliation": "Dana-Farber Cancer Institute", 
            "last_name": "Harold Burstein, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "June 2003", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Phase I: To evaluate the safety, tolerability and and MTD of several dose levels of CPG 7909 of CPG 7909 in combination with the standard Herceptin\u00ae treatment in patients with metastatic breast cancer", 
                "safety_issue": "Yes"
            }, 
            {
                "measure": "Phase II: Evaluate tumor response and safety of CPG 7909 in combination with Herceptin\u00ae in patients with metastatic breast cancer", 
                "safety_issue": "No"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00031278"
        }, 
        "responsible_party": {
            "name_title": "Director, Clinical Trial Disclosure Group", 
            "organization": "Pfizer, Inc."
        }, 
        "secondary_outcome": [
            {
                "measure": "Phase I: To evaluate tumor response, duration of response, time to disease progression, and survival time", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Phase II: To evaluate duration of response, time to disease progression, and survival time", 
                "safety_issue": "No"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2001", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2011"
    }, 
    "geocoordinates": {
        "Cancer Center at Saint Barnabas Medical Center": "40.786 -74.33", 
        "Cancer Research Network, Inc.": "26.128 -80.233", 
        "Comprehensive Cancer Center, University of Michigan": "42.281 -83.743", 
        "Dana-Farber Cancer Institute": "42.358 -71.06", 
        "Fletcher Allen Health Care": "44.476 -73.212", 
        "Greenebaum Cancer Center at Univ. of Maryland": "39.29 -76.612", 
        "Univ. of Connecticut Health Center": "41.728 -72.84", 
        "Univ. of Pittsburgh Cancer Institute, Magee Women's Hosp.": "40.441 -79.996"
    }
}